domingo, 15 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 25, 2026

Qualcomm Is Down 24% in 2026 and Just Announced a $20 Billion Buyback. Is That Bullish or a Warning Sign?

View original at nasdaq.com
“Long-term debt is manageable at $14.8 billion, and Qualcomm has generated $12.9 billion in trailing free cash flow.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Qualcomm's partnership with Apple could end this year, as Apple is developing its own custom-designed modem chips

    60% confidence
  • Qualcomm was not one of the 10 best stocks for investors to buy now

    60% confidence
  • Stock Advisor's total average return is 913%, a market-crushing outperformance compared to 185% for the S&P 500

    60% confidence
  • The memory shortage is impacting Qualcomm's smartphone component sales, which is its core business

    60% confidence
  • The memory shortage is impacting Qualcomm's smartphone component sales, which is its core business

    60% confidence
  • Qualcomm may be undervalued at the moment

    60% confidence
  • Qualcomm may be undervalued at the moment

    60% confidence
  • I'd personally hold off on investing for now, at least until seeing more progress in automotive and IoT revenue

    60% confidence
  • The 10 best stocks for investors to buy now do not include Qualcomm

    60% confidence
  • Stock Advisor's total average return is 913% compared to 185% for the S&P 500

    60% confidence
  • Qualcomm looks cheap right now, trading at 12 times forward earnings

    60% confidence
  • Would personally hold off on investing in Qualcomm for now, at least until seeing more progress in automotive and IoT revenue

    60% confidence
  • The memory shortage is impacting Qualcomm's smartphone component sales

    60% confidence
  • Qualcomm can afford both the buyback and dividend as it has a solid balance sheet with $7.2 billion in cash and $12.9 billion in trailing free cash flow

    60% confidence
  • The Motley Fool Stock Advisor analyst team identified 10 best stocks for investors to buy now and Qualcomm wasn't one of them

    60% confidence
  • Qualcomm's partnership with Apple could end this year, as Apple is developing its own custom-designed modem chips

    60% confidence
  • The buyback may be undervalued at the moment, but I'd personally hold off on investing until seeing more progress in automotive and IoT revenue

    60% confidence
  • Qualcomm's partnership with Apple could end this year as Apple develops its own custom-designed modem chips

    60% confidence

Data points we hold from this source

Qualcomm Incorporated · forward pe ratio12 ratio
Qualcomm Incorporated · quarterly dividend0.92 USD
Qualcomm Incorporated · stock return11 percent
Qualcomm Incorporated · total return229 percent
Qualcomm Incorporated · pe ratio forward12 ratio
Qualcomm Incorporated · free cash flow12.9 USD
Qualcomm Incorporated · dividend quarterly0.89 USD
Qualcomm Incorporated · free cash flow12.9 USD
Qualcomm Incorporated · quarterly dividend0.89 USD
Qualcomm Incorporated · debt14.8 USD
Qualcomm Incorporated · cash7.2 USD
Qualcomm Incorporated · iot revenue1.7 USD
Qualcomm Incorporated · automotive revenue1.1 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,580 documentos fuente archivados
Consulta estos datos → isubstrate.com